Purpose: Metastatic cancers of unknown primary or with unclear diagnoses pose diagnostic and management challenges, often leading to poor outcomes. Studies of the 92-gene assay have demonstrated improved diagnostic accuracy compared with standard pathology techniques and improved survival in patients treated on the basis of assay results. The current study assessed the clinical impact of the 92-gene assay on diagnostic and treatment decisions for patients with unknown or uncertain diagnoses.
Methods: Patients in this prospective, multi-institutional, decision-impact study included those for whom the 92-gene assay was ordered as part of routine care. Participating physicians completed electronic case report forms that contained standardized, specialty-specific questionnaires. Data collection included patient and tumor characteristics and clinical history. The key study objective of clinical impact was calculated on the basis of changes in final diagnosis and treatment after testing.
Results: Data collection included 444 patients, 107 physicians (73 oncologists and 34 pathologists), and 28 sites. Molecular diagnoses from 22 different tumor types and subtypes across all cases were provided in 95.5% of patients with a reportable result (n = 397). Physicians reported that the 92-gene assay was used broadly for diagnostic dilemmas that ranged from single suspected tumor type (29%) to a differential diagnosis of two or more suspected tumor types (30%) or cancers of unknown primary (41%). Integration of 92-gene assay results led to a change in the recommended treatment in 47% of patients.
Conclusion: Findings from this clinical utility study demonstrate that the 92-gene assay led to a change in treatment decisions in every other patient case. These data additionally define the role of this assay in clinical practice and strongly support the consideration of molecular tumor typing in the diagnosis and treatment planning of patients with metastatic cancer with unknown or uncertain diagnosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/PO.17.00145 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immune microenvironment modulation following neoadjuvant therapy for oesophageal adenocarcinoma: a translational analysis of the DEBIOC clinical trial.
ESMO Open
November 2024
Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast. Electronic address:
Article Synopsis
- - The DEBIOC trial explored the safety and efficacy of neoadjuvant treatment using oxaliplatin and capecitabine (Xelox) with or without AZD8931 in patients with oesophageal adenocarcinoma, showing moderate safety but limited effectiveness.
- - Researchers analyzed genetic data from 25 pre-treatment and 18 post-treatment biopsy samples to examine how these treatments influenced biological pathways related to cancer through advanced software tools.
- - Their findings identified three molecular subgroups linked to immune response, with treatment affecting immune signaling and tumor-infiltrating lymphocytes, while the addition of AZD8931 promoted a less favorable immunosuppressive environment and common cancer resistance mechanisms.
Impact of protein kinase CK2 downregulation and inhibition on oncomir clusters 17 ~ 92 and 106b ~ 25 in prostate, breast, and head and neck cancers.
Mol Med
October 2024
Research Service, Minneapolis VA Health Care System, Minneapolis, MN, 55417, USA.
Article Synopsis
- * A study used PCR analysis to observe how downregulating CK2 affects the levels of specific oncomir clusters (miR-17 ~ 92 and miR-106b ~ 25) in different cancer cell types, including prostate and breast cancers.
- * Results indicated that reducing CK2 expression or activity significantly lowered the levels of these oncomirs, suggesting a potential link between CK2 and the regulation of these specific microRNAs in cancer cells.
Purpose: Cancer of unknown primary (CUP) is a syndrome comprising metastatic cancers without a clinically identified primary site. Although patients with CUP have an unfavorable prognosis, treatment with site-specific therapies guided by clinical features, standard pathology, and molecular assays can improve overall survival. The 92-gene assay (CancerTYPE ID) is a gene expression-based classifier that helps identify the tissue of origin for metastatic cancers with unknown or uncertain diagnoses.
View Article and Find Full Text PDFAssociation between Mir-17-92 gene promoter polymorphisms and depression in a Chinese population.
BMC Med Genomics
May 2024
Department of Pathology and Pathophysiology, School of Basic Medical Sciences, Chengdu Medical College, Chengdu, 610500, Sichuan, P.R. China.
Background: Depression is a common chronic debilitating disease with a heavy social burden. single nucleotide polymorphisms (SNPs) can affect the function of microRNAs (miRNAs), which is in turn associated with neurological diseases. However, the association between SNPs located in the promoter region of miR-17-92 and the risk of depression remains unclear.
View Article and Find Full Text PDF[Comparison of Three Different Methods in Investigating the Molecular Epidemiology of Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates].
Mikrobiyol Bul
April 2024
Karadeniz Technical University Faculty of Health Sciences, Department of Health Management, Trabzon, Türkiye.
The aim of the study was to evaluate the relationship between carbapenem-resistant Acinetobacter baumannii isolates carrying oxacillinase-type carbapenemase genes with "international high-risk clones" (IC I, II, and III) by different molecular epidemiological methods and to statistically compare the concordance and discrimination power of the methods. Carbapenem-resistant and moderately susceptible A.baumannii isolates from non-repeating blood cultures of 72 patients were included in the study.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!